Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cystic Fibrosis Buyers’ Club

- PMLiVE

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

With rapid growth comes growing pains...

Impetus Digital

Profile pics of Priti and Tijana

Genesis Research Insights & Evidence webinar 20 Oct: Reserve your place!

Join Priti Jhingran of Genesis Research and Tijana Ignjatovic of Market Access Transformation (MAT) for their webinar 'Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to...

Genesis Research Group

- PMLiVE

Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes

Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production

- PMLiVE

Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn

A new deal will see Vertex harness Arbor Biotechnologies gene-editing technology to enhance its discovery efforts

- PMLiVE

Vertex to lead development of CRISPR Therapeutics-partnered gene therapy

Amended agreement sees Vertex take control of gene therapy programme

- PMLiVE

Vertex gains FDA fast track designation for diabetes stem cell therapy

Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients

- PMLiVE

Moderna inks R&D agreements with Vertex and Chiesi

Biotech agrees to separate deals for the development of gene-editing and mRNA therapies

- PMLiVE

Vertex’s triple combination CF therapy to become available on the NHS

The drug will immediately become available to thousands of cystic fibrosis patients

- PMLiVE

CRISPR gene-editing in cancer patients is safe, according to new study

Patients had no side effects following CRISPR treatment

- PMLiVE

Vertex continues upward trajectory with French Orkambi deal

Comes on the heels of similar reimbursement deal in England

- PMLiVE

Vertex reveals promising data from first CRISPR-treated patients

Investigational gene therapy has potentially curative effect

- PMLiVE

Vertex, NHS England and NICE finally reach agreement for Orkambi

Deal also includes Vertex’s other licensed cystic fibrosis medicines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links